Prolight Diagnostics

0,20 SEK

0,00 %

Mindre end 1K følgere

PRLD

Nordic SME

Medical Equipment & Services

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Investorkonsensus

0,00 %

-2,97 %

-18,33 %

-17,00 %

+59,80 %

+55,17 %

+14,51 %

-88,57 %

-50,20 %

Prolight Diagnostics develops point-of-care (POC) systems. These are small mobile instruments with disposable test cards that can perform In-Vitro Diagnostic (IVD) tests from a drop of blood. The POC system can contribute to faster and more accurate diagnoses of acute conditions. The company's launch product will be a highly sensitive measurement of troponin to be able to determine and exclude heart attacks.

Markedsværdi

236,08 mio. SEK

Aktieomsætning

163,13 t SEK

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Omsætning og EBIT-margin

Omsætning

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

26.2

2026

Årsrapport '25

26.5

2026

Delårsrapport Q1'26

26.5

2026

Generalforsamling '26

Alle

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Pressemeddelelsefor 7 timer siden

BioStock publishes an article describing how Prolight Diagnostics is preparing the clinical study

Prolight Diagnostics

Pressemeddelelsefor 9 timer siden

BioStock: Prolight's CTO focuses on CRO partner MDx

Prolight Diagnostics

Selskabsmeddelelse5.12.2025, 10.00

THE NOMINATION COMMITTEE APPOINTED FOR THE ANNUAL GENERAL MEETING 2026

Prolight Diagnostics

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse4.12.2025, 09.00

Prolight announces timetable for share reverse split

Prolight Diagnostics

Selskabsmeddelelse27.11.2025, 07.00

Prolight Diagnostics publishes quarterly report Q3, 2025

Prolight Diagnostics

Selskabsmeddelelse19.11.2025, 13.45

Extraordinary general meeting of Prolight Diagnostics AB (publ) on 19 November 2025

Prolight Diagnostics

Pressemeddelelse17.11.2025, 11.40

BioStock publishes article about Prolight Diagnostics continued preparations to bring the Psyros platform to market

Prolight Diagnostics

Pressemeddelelse17.11.2025, 10.26

BioStock: Final adjustments and validation take center stage at Prolight Diagnostics

Prolight Diagnostics

Pressemeddelelse5.11.2025, 13.55

Prolight Diagnostics publishes investor letter for November 2025

Prolight Diagnostics

Selskabsmeddelelse17.10.2025, 10.00

NOTICE OF EXTRAORDINARY GENERAL MEETING IN PROLIGHT DIAGNOSTICS AB (PUBL)

Prolight Diagnostics

Pressemeddelelse29.8.2025, 11.40

Emergers publishes updated analysis for Prolight Diagnostics

Prolight Diagnostics

Eksterne analyser29.8.2025, 06.18

Prolight: Financing and partner interest strengthen case ahead of regulatory study - Emergers

In Q2, Prolight reported initial positive data from its ongoing whole blood study at St Thomas’ Hospital in London, showing equivalence between whole blood and plasma and thereby confirming the robust clinical performance of the PsyrosTM POC platform...

Prolight Diagnostics

Pressemeddelelse29.8.2025, 06.00

Emergers: Equity Research | PROLIGHT: Financing and partner interest strengthen case ahead of regulatory study

Prolight Diagnostics

Selskabsmeddelelse28.8.2025, 06.00

Prolight Diagnostics publishes half-year report, 2025

Prolight Diagnostics

Pressemeddelelse27.8.2025, 06.00

Prolight receives Notice of Intention to Grant in Europe for third Psyros™ patent

Prolight Diagnostics

Pressemeddelelse1.8.2025, 09.00

Prolight Diagnostics publishes investor letter for August 2025

Prolight Diagnostics

Pressemeddelelse21.7.2025, 06.00

Prolight secures patent in Japan for Psyros™ technology

Prolight Diagnostics

Selskabsmeddelelse15.7.2025, 12.00

Last day of trading in BTAs – conversion of BTAs into shares

Prolight Diagnostics

Eksterne analyser3.7.2025, 07.19

Prolight: Fully subscribed rights issue strengthens Psyros case ahead of commercial partnerships - Emergers

Prolight announced that its rights issue was fully subscribed, eliminating near-term financing risk and securing the capital needed to finalise the development, verification and pilot production of the PsyrosTM system. The broad participation from the...

Prolight Diagnostics

Pressemeddelelse3.7.2025, 06.00

Emergers: Equity Research | PROLIGHT: Fully subscribed rights issue strengthens Psyros case ahead of commercial partnerships

Prolight Diagnostics

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.